Matthew R. Smith, MD, PhD
Dr. Smith’s research centers on novel therapy, prevention and treatment of bone metastases, and survivorship in men with prostate cancer. His research is best demonstrated through his studies in prostate cancer survivorship. Hormone therapy improves disease-specific outcomes in men with prostate cancer but treatment-related gonadal steroid deficiency has a variety of adverse effects. Dr. Smith leads a clinical research program to characterize, understand, and prevent the adverse effects of gonadal steroid deficiency in prostate cancer survivors. Using population-based and prospective observational studies, his group has demonstrated that osteoporosis, obesity, and obesity-related disease are important clinical complications of hormone therapy. In related translational studies, he has also helped define the mechanisms of treatment-related osteoporosis, diabetes, and cardiovascular disease. He currently leads large randomized controlled trials to evaluate novel strategies to prevent treatment-related fractures. He also leads randomized controlled trials to prevent and treat bone metastases in men with advanced prostate cancer.